|Day Low/High||75.95 / 78.34|
|52 Wk Low/High||60.89 / 85.97|
Rarely do investors get to buy these types of quality businesses at such discounted prices.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
The sector seems to be rebounding after tumbling by more than 40%.
That may be the best way to get through the notorious month of August.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose. " --Blondie, "The Good, The Bad and The Ugly" Strange references often jump off of the page as I write my diary and my mind wanders and free-associ...
"There are two kinds of people in the world, my friend: Those with a rope around the neck and the people who have the job of doing the cutting." Tuco The Ugly, The Good, The Bad and The Ugly Strange references often jump off of the page as I write m...
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
Beware of false profits. Monday's "takeaway." Radian Group was up a second day in a row after a nice, 25%-plus run. Thank you, Barron's. My Trade of the Week, long SPDR S&P 500 ETF puts. Here's why... My take on the technicals. A deeper dive into...
United Technologies is taking share from competitors like General Electirc.
Good enough, tied with a good story, is pushing post-earnings bumps today.
Let's make August $217 monthly puts of the SPDR S&P 500 ETF our Trade of the Week. These puts closed at $2.50 yesterday, and this is a bearish bet. There are several reasons why I feel stocks could decline over the near term, including: Continuing O...
"Beware of false prophets, who come to you in sheep's clothing but inwardly are ravenous wolves." -- Matthew 7:15 I try to exclude personal experiences from my diary and only include observations related to the markets. But I have to start the morni...
One is rising on a minor sales bump while the other is falling despite solid results; and here is why.
With chaos blaring in the headlines, market players simple shrug.
It has been great standing in for Doug Kass today. Evidently, Monday has a more engaged investor audience than my usual Friday beat. There were more than 200 comments today in a very lively back-and-forth session. It made what was a dull trading day...
The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...
The market is starting to spot larger losses. The energy sector is the big loser so far. With oil heading down to $43 a barrel, the segment is down more than 2% on the day. Despite what many regarded as a divided Republican National Convention, GOP ...
Earnings reports will test the timeframe mettle for some investors and traders.
The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.
The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...
Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.
A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.
The biotech juggernaut still has a lot going for it, especially at these levels.
An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.
Each bounce in the stock has been followed by a move to lower lows.
A look at who will be up and who will down this earnings season.
They need to do something that makes them stand out as stocks you want to own, not avoid.